Niraparib With beVAcizumab After Complete cytoreductioN in Patients With ovArian Cancer

Phase 2 Recruiting 390 enrolled ARCAGY/ GINECO GROUP

RandomizedParallel-groupOpen-labelTreatment

Summary

Randomized, open label, phase II multicenter study to assess the efficacy niraparib versus niraparib +bevacizumab maintenance in patients with newly diagnosed stage IIIA/B/C high-grade epithelial ovarian cancer with no residual disease after frontline surgery and treatment by adjuvant platinum-basedchemotherapy +/-bevacizumab.

Timeline

Start: 2022-02-01
Primary completion: 2027-02
Completion: 2032-02-01

Publications

Sghaier S, Corbaux P, Ray-Coquard I, Lim MC, Hasegawa K, Nieuwenhuysen EV, Gonzalez A, Raspagliesi F, Freyer G. NIRVANA-1: maintenance therapy with niraparib versus niraparib-bevacizumab in patients with advanced ovarian cancer. Future Oncol. 2023 Aug;19(25):1715-1727. doi: 10.2217/fon-2023-0167. Epub 2023 Aug 31.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Bevacizumab	Monoclonal antibody	15 mg/kg	Intravenous
Subject	Niraparib	Small molecule	200 mg	Oral
Subject	Niraparib	Small molecule	300 mg	Oral
Background	Carboplatin	Small molecule	5 unknown	Intravenous
Background	Carboplatin	Small molecule	6 unknown	Intravenous
Background	Paclitaxel	Small molecule	175 mg/m2	Intravenous

Niraparib With beVAcizumab After Complete cytoreductioN in Patients With ovArian Cancer

Summary

Timeline

Publications

Drugs

Indications